Price Alert

Certara Inc. (CERT)

NASDAQ: CERT · Real-Time Price · USD

11.16

0.19 (1.73%)

At close: Aug 15, 2025, 10:01 AM

1.73% (1D)

Bid	11.11
Market Cap	1.79B
Revenue (ttm)	405.75M
Net Income (ttm)	7.98M
EPS (ttm)	0.05
PE Ratio (ttm)	223.3
Forward PE	19.54
Analyst	Buy

Ask	11.17
Volume	90,509
Avg. Volume (20D)	1,674,485
Open	11.04
Previous Close	10.97
Day's Range	10.97 - 11.24
52-Week Range	8.63 - 15.69
Beta	1.42

About CERT

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CERT

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CERT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Certara has released their quartely earnings on Aug 6, 2025:

Revenue of $104.6M exceeds estimates by $726.84K, with 12.10% YoY growth.

EPS of 0.07 misses estimates by -0.01, with 0.00% YoY growth.

Next Earnings Release

Certara Inc. is scheduled to release its earnings on Nov 5, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

-11.03%

Certara shares are trading lower following Q1 repo... Unlock content with Pro Subscription

4 months ago

+11.54%

Certara shares are trading higher after the company issued a year-over-year increase in its Q1 revenue guidance and announced a $100 million share repurchase program. Additionally, the company announced it launched a non-animal navigator solution to help drug developers reduce reliance on animal testing.

News

1 week ago · seekingalpha.com

Certara, Inc. (CERT) Q2 2025 Earnings Call Transcript

Certara, Inc. (NASDAQ:CERT ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants John E. Gallagher - SVP, Principal Accounting Officer & Chief Financial Officer William F.

1 week ago · fool.com

Certara (CERT) Q2 Revenue Jumps 12%

Certara (CERT -3.35%), a leader in biosimulation software and Model-Informed Drug Development solutions, released its Q2 FY2025 earnings on August 6, 2025. The most notable news was a slight revenue b...

1 week ago · zacks.com

Certara, Inc. (CERT) Q2 Earnings Miss Estimates

Certara, Inc. (CERT) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago.

2 weeks ago · zacks.com

Certara, Inc. (CERT) Reports Next Week: Wall Street Expects Earnings Growth

Certara (CERT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago · zacks.com

Will Certara (CERT) Beat Estimates Again in Its Next Earnings Report?

Certara (CERT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

1 month ago · seekingalpha.com

Certara: Ideally Positioned To Benefit From IT Innovation In Life Sciences

Certara is a leader in Model-Informed Drug Development (MIDD), offering essential software and services that reduce drug development costs and time. The company's diversified software portfolio and gr...

1 month ago · fool.com

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.